About Frontier Biotechnologies Inc. Company

The company was founded in 2013 and is committed to the research, development, production and sale of new drugs that do not meet major clinical needs. The company was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange in October 2020. It is a national specialized, new, small giant enterprise and a national high-tech enterprise. The company is mainly engaged in R&D, production and sales of antiviral and musculoskeletal pain treatment drugs. The company's main products: aconin, long-acting anti-HIV drugs, micronucleic acid drugs, osteoporosis treatment product FB4001, hot melt adhesives. Corporate honors: “24th China Patent Gold Award” and “First Jiangsu Patent Award Excellence Award”. The company won the honorary title of “Jiangsu Specialized and New Small and Medium Enterprises”, “China's Top 30 Innovative Small Molecule Pharmaceutical Enterprises of the Year”, “2022 Biotechnology Innovation Award”, “2022 Investment Pioneer Award”, “2022 China Biomedical Industry Value List Top 10 Most Growing Small Molecule Innovative Drug Companies”; in 2022, it won the honorary title of “2022 China Investment Pioneer Award”, 2018 China's Top Ten Medical Science and Technology News, 2018 Innovative Drugs Innovative enterprises, 2016 Jiangsu Double Innovation Team, Key Overseas Chinese Entrepreneurship Teams, Outstanding Enterprises in the 6th China Innovation and Entrepreneurship Competition, “2024 Jiangsu Health Industry Research Association Member Units”, etc.